Blood cell features in myeloproliferative neoplasms
Part of Blood & lymphatic clinical trials.
This study looks at whether certain blood cell features can help doctors better understand myeloproliferative neoplasms. By analyzing blood samples, they hope to find new clues that could improve diagnosis and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a myeloproliferative neoplasm (MPN), such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
- Your diagnosis must follow the latest World Health Organization (WHO) criteria.
- You cannot have any other type of blood cancer (for example, myelodysplastic syndrome or acute leukemia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study looks at whether a simple blood test can give the same information as a bone marrow biopsy for people with myeloproliferative neoplasms (MPNs), which are blood cancers that cause the bone marrow to make too many cells. If successful, it could mean less invasive testing for patients.
This study looks at heart and blood vessel problems in people with certain blood cancers called myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and primary myelofibrosis. It aims to understand how these conditions affect the heart and blood vessels, which may lead to better care.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
Hear when a new Myeloproliferative Neoplasms (MPNs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.